High radiation dose in chemoradiotherapy followed by immunotherapy with durvalumab in patients with stage III non-small cell lung cancer does not increase risk for pneumonitis
70 Gy radiation dose for CCRT followed by durvalumab is a safe regimen and may provide clinical benefits in NSCLC patients compared to lower doses. Pneumonitis incidence aligns with previous literature. The higher dose is associated with improved overall survival, and reduced disease progression, potentially due to a longer consolidation time.
Authors
- Klaus Hackner (ORCID: https://orcid.org/0000-0002-6378-5840)
- Peter Errhalt (ORCID: https://orcid.org/0000-0003-3556-4917)
- Nguyen‐Son Le (ORCID: https://orcid.org/0000-0001-8329-3037)
- Felix Schragel (ORCID: https://orcid.org/0009-0006-7019-8325)
- Melanie Matousek
- Christoph Resl
- Gudrun Kreye (ORCID: https://orcid.org/0000-0003-0674-7079)
- Petra Georg
Institutions
- Karl Landsteiner University of Health Sciences (AT)
Publication Details
- Journal
- Strahlentherapie und Onkologie
- Published
- 2025-02-13
- DOI
- https://doi.org/10.1007/s00066-025-02369-0
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karl Landsteiner Privatuniversität für Gesundheitswissenschaften